2018
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin
Vashisht R, Jung K, Schuler A, Banda J, Park R, Jin S, Li L, Dudley J, Johnson K, Shervey M, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich C, Weaver J, Schuemie M, Ryan P, Callahan A, Shah N. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin. JAMA Network Open 2018, 1: e181755. PMID: 30646124, PMCID: PMC6324274, DOI: 10.1001/jamanetworkopen.2018.1755.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitorsDipeptidyl peptidase-4 inhibitorsFirst-line therapyPeptidase-4 inhibitorsSecond-line drugsType 2 diabetesMyocardial infarctionEye disordersKidney disordersDrug classesSecond-line treatment choiceTotal hemoglobinObservational Health Data SciencesSecond-line treatment optionNew-user cohort studyEffectiveness of sulfonylureasSecond-line treatmentHemoglobin A1c levelsUse of sulfonylureasHealth Data SciencesLarge international studyElectronic medical recordsRoutine medical practiceInsurance claims dataCohort study
2011
Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record
Delaney J, Ramirez A, Bowton E, Pulley J, Basford M, Schildcrout J, Shi Y, Zink R, Oetjens M, Xu H, Cleator J, Jahangir E, Ritchie M, Masys D, Roden D, Crawford D, Denny J. Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record. Clinical Pharmacology & Therapeutics 2011, 91: 257-263. PMID: 22190063, PMCID: PMC3621954, DOI: 10.1038/clpt.2011.221.Peer-Reviewed Original ResearchMeSH KeywordsAgedAryl Hydrocarbon HydroxylasesAryldialkylphosphataseATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1ClopidogrelCytochrome P-450 CYP2C19Databases, Nucleic AcidElectronic Health RecordsFemaleGenotypeHumansMaleMyocardial InfarctionPharmacogeneticsPlatelet Aggregation InhibitorsPolymorphism, GeneticStentsThrombosisTiclopidineTreatment OutcomeConceptsPercutaneous coronary interventionElectronic health recordsCardiac eventsMyocardial infarctionRecurrent cardiac eventsRecurrent cardiovascular eventsHealth recordsUse of EHRsClopidogrel therapyCardiovascular eventsClopidogrel treatmentClopidogrel resistanceClopidogrel responseCoronary interventionStent thrombosisReal-world settingCYP2C19ABCB1PON1Pharmacogenomic studiesRecurrent eventsTreatmentDNA repositoryDNA samplesInfarction